Search research articles
Contact Us
Filters
Showing results (651-660 of 742) with videos related to
Page
of 75
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
D S Hong, T M Bauer, J J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology
|
June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T Shaw, Tae Min Kim, Lucio Crinò, et al.
The Science of the Total Environment
|
February 19, 2024
Equipping for risk: Lessons learnt from the UK shale-gas experience on assessing environmental risks for the future geoenergy use of the deep subsurface
P L Smedley, G Allen, B J Baptie, et al.
Science Immunology
|
June 21, 2020
Rate of replenishment and microenvironment contribute to the sexually dimorphic phenotype and function of peritoneal macrophages
C C Bain, D A Gibson, N J Steers, et al.
Cancer Discovery
|
March 28, 2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
Jim Sang, Jaime Acquaviva, Julie C Friedland, et al.
The Lancet. Respiratory Medicine
|
December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
Benjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2018
Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
Caroline E McCoach, Collin M Blakely, Kimberly C Banks, et al.
Future Oncology (London, England)
|
October 3, 2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer
Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i>-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.
Page
of 75
Search research articles
Search
Showing results (651-660 of 742) with videos related to
Sort By:
Page
of 75
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
D S Hong, T M Bauer, J J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology
|
June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T Shaw, Tae Min Kim, Lucio Crinò, et al.
The Science of the Total Environment
|
February 19, 2024
Equipping for risk: Lessons learnt from the UK shale-gas experience on assessing environmental risks for the future geoenergy use of the deep subsurface
P L Smedley, G Allen, B J Baptie, et al.
Science Immunology
|
June 21, 2020
Rate of replenishment and microenvironment contribute to the sexually dimorphic phenotype and function of peritoneal macrophages
C C Bain, D A Gibson, N J Steers, et al.
Cancer Discovery
|
March 28, 2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
Jim Sang, Jaime Acquaviva, Julie C Friedland, et al.
The Lancet. Respiratory Medicine
|
December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
Benjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2018
Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
Caroline E McCoach, Collin M Blakely, Kimberly C Banks, et al.
Future Oncology (London, England)
|
October 3, 2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer
Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i>-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.
Page
of 75